pharma · Unresectable Hepatocellular Carcinoma (HCC) · Unexplained Recurrent Miscarriage and Recurrent Implantation Failure
Zenshine Pharmaceuticals
Nanjing Zenshine Pharmaceuticals
Nanjing Zenshine Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Unresectable Hepatocellular Carcinoma (HCC), Unexplained Recurrent Miscarriage and Recurrent Implanta
CN HQ
2018 Founded
12 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2018
- Employees
- 12
- Programs
- 8
- Drugs
- 17
- Patents
- 0
Rezvilutamide
Phase 2 · small molecule · Prostate Cancer
Rezvilutamide for Prostate Cancer is a Phase 2 program (small_molecule) at Nanjing Zenshine Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code IUNU-PC-120
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Nanjing Zenshine Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Prostate Cancer
- Status
- active
- Trials
- 1